Complix NV of Belgium, which is developing protein-based therapeutics against intracellular disease targets, has appointed Yvonne McGrath, previously of Immunocore Ltd, as its chief scientific officer. She will replace Ignace Lasters, a co-founder of Complix, who becomes chief technology officer. At Immunocore, Dr McGrath was most recently head of development and before that, head of preclinical development and of chemistry, manufacturing and controls (CMC). Prior to working for Immunocore, she was a project manager at MediGene AG.
Dr McGrath has a PhD from the University of Wales College of Medicine.
Complix announced the appointment on 16 May 2014.
Copyright 2014 Evernow Publishing Ltd